



## SVB Securities Served as PIPE Placement Agent to Frazier Lifesciences Acquisition Corp. (Nasdaq: FLAC) and Financial Advisor and Capital Markets Advisor to NewAmsterdam Pharma in Connection with its Completed Merger and \$235 Million PIPE

### Key Transaction Highlights

- On November 23rd, NewAmsterdam Pharma Company N.V. (“NewAmsterdam”) and Frazier Lifesciences Acquisition Corp. (“FLAC”) announced the closing of their business combination.
- The resulting combined company commenced trading its ordinary shares and warrants on Wednesday, November 23rd on the Nasdaq Capital Market under the symbols “NAMS” and “NAMSW,” respectively.
- As a result of the business combination, NewAmsterdam received total net proceeds of approximately \$328 million, combining approximately \$93 million from the former FLAC trust account (**reflecting a final redemption rate of approximately 32 percent**) and the concurrent \$235 million PIPE financing led by Frazier Healthcare Partners and Bain Capital Life Sciences, which the Company expects will extend cash runway through 2026, beyond all expected Phase 3 readouts for cardiovascular disease, including the PREVAIL CVOT study.

### About NewAmsterdam Pharma

NewAmsterdam is a clinical-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been sufficiently successful or well tolerated. NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, as the preferred LDL-C lowering therapy to be used as an adjunct to maximally tolerated statin therapy for high-risk cardiovascular disease (“CVD”) patients. Results from NewAmsterdam’s ROSE Phase 2b trial (presented at AHA Scientific Sessions in 2021) included observations that patients receiving obicetrapib 10 mg experienced a median reduction in LDL-C of 51% versus baseline in patients on high intensity statin therapy (vs. a 7% reduction in the placebo arm). NewAmsterdam is headquartered in the Netherlands.

### About Frazier Lifesciences Acquisition Corporation

FLAC is blank check company incorporated as a Cayman Islands exempted company in October 2020 for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities. FLAC was formed to leverage the extensive experience and track record of its management team with the goal of financing a company that can both develop transformative therapies for patients in need and deliver significant returns to its investors.

If you would like to unsubscribe from this distribution, click [here](#). If you would like to unsubscribe from all SVB Securities distributions, click [here](#).

THIS EMAIL IS FOR INFORMATIONAL PURPOSES ONLY AND IS BEING FURNISHED TO INVESTMENT BANKING CLIENTS OF SVB SECURITIES LLC. THE INFORMATION INCLUDED HEREIN IS FOR YOUR INFORMATION ONLY AND MAY NOT BE REPRODUCED FOR OR REDISTRIBUTED TO ANY OTHER PURPOSES. THIS EMAIL IS NOT AN OFFER TO SELL, AND IS NOT SOLICITING AN OFFER TO BUY, ANY SECURITIES.

**BOSTON**  
53 State Street  
40th Floor  
Boston, MA 02109

**CHARLOTTE**  
227 West Trade Street  
Suite 2050  
Charlotte, NC 28202

**NASHVILLE**  
40 Burton Hills Boulevard  
Suite 200  
Nashville, TN 37215

**NEW YORK**  
1301 Avenue of the Americas  
12th Floor  
New York, NY 10019

**SAN FRANCISCO**  
255 California Street  
12th Floor  
San Francisco, CA 94111